Inhibition of Corneal Neovascularization by Topically Administered Propranolol in A Rabbit Model

Objective: To evaluate the effects of topical propranolol for treatment of the corneal neovascularization (CNV) in a rabbit model of corneal injury. Methods: The CNV model was induced by 3 sutures of the cornea in 20 rabbits (20 corneas). 2 weeks after CNV, all sutures were removed then rabbits were divided randomly into two groups: Groups 1 received topical propranolol 10 mg/mL and Group 2 received only topical normal saline drops as control group, in the right eyes three times a day for 2 weeks. Photographs of (CNV) were obtained before drug administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Image J1.49c software. Results: The mean percentage of CNV area estimated as 100% before treatment. At the 1 week after treatment, the mean percentage of NV area in propranolol and saline group were 78.01 ± 4.16 and 93.33 ± 4.57, respectively. Moreover, at the 2 weeks after treatment were 65.72 ± 4.15 and 84.96 ± 5.21, respectively. After 1 and 2 weeks treatment, the NV area in propranolol group was regressed more than saline group significantly (P < 0.0001). Conclusion: Topical administration of propranolol reduces CNV in the short-term, but the efficacy of long-term treatment needs more investigations.

[1]  H. Önder,et al.  The effect of β receptor blockade through propranolol on corneal neovascularization. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[2]  E. Masini,et al.  Pharmacokinetics and local safety profile of propranolol eye drops in rabbits , 2014, Pediatric Research.

[3]  Yasin Cinar,et al.  Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model , 2014, Cutaneous and ocular toxicology.

[4]  H. Tchah,et al.  Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization. , 2013, International journal of ophthalmology.

[5]  P. Bagnoli,et al.  Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. , 2013, Experimental eye research.

[6]  N. Lee,et al.  Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model , 2013, Cornea.

[7]  R. Erdoğan Comparison of subconjunctivally injected bevacizumab , ranibizumab , and pegaptanib for inhibition of corneal neovascularization in a rat model 窑 , 2013 .

[8]  J. Pérez-Santonja,et al.  [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model]. , 2013, Archivos de la Sociedad Espanola de Oftalmologia.

[9]  D. Azar,et al.  Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.

[10]  A. Karalezli,et al.  Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model , 2012, Ophthalmic Research.

[11]  U. Keklikçi,et al.  The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  R. Dana,et al.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). , 2012, The ocular surface.

[13]  H. Hosseini,et al.  Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease , 2012, Cornea.

[14]  Terry Kim,et al.  Anatomy and physiology of the cornea , 2011, Journal of cataract and refractive surgery.

[15]  Hadi Z-Mehrjardi,et al.  Prevention of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Its Topical Form in Experimental Rats , 2011, Ophthalmic Research.

[16]  P. Fortunato,et al.  Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. , 2011, Investigative ophthalmology & visual science.

[17]  J. Alió,et al.  Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. , 2010, American journal of ophthalmology.

[18]  Terry Kim,et al.  Inhibition of Experimental Corneal Neovascularization by Using Subconjunctival Injection of Bevacizumab (Avastin) , 2008, Cornea.

[19]  김태임,et al.  Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). , 2008 .

[20]  R. Simó,et al.  Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. , 2006, Current diabetes reviews.

[21]  V. Bhalla,et al.  inhibition in , 2005 .

[22]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[23]  D. Azar,et al.  Corneal neovascularization. , 2001, Current opinion in ophthalmology.

[24]  A. Adamis,et al.  Ocular neovascularization: an epidemiologic review. , 1998, Survey of ophthalmology.